We have entered into an At Market Issuance Sales Agreement (the “Sale Agreement”) with B. Riley Securities, Inc., BTIG, LLC, and H.C.At Market Issuance Sales Agreement • July 27th, 2021 • New York
Contract Type FiledJuly 27th, 2021 JurisdictionWe are a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics. We apply a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise diagnostic sampling and drug delivery solutions. Our vision is to transform healthcare to become more precise and personal by improving the diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.